Floatz logo

Nirogacestat

Ovarian Granulosa Cell Tumor

SpringWorks Therapeutics, Inc.Small moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Ovarian Granulosa Cell Tumor cohort.

Asset / SponsorPhaseRating
Arimidex
Memorial Sloan Kettering Cancer Center
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 2CCC
Carboplatin
GOG Foundation
Phase 2CCC
ETOPOSIDE
GOG Foundation
Phase 2CCC
BLEOMYCIN
GOG Foundation
Phase 2CCC

View all 14 →

Same molecule, other indications

Nirogacestat is also rated in:

neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
ovarian granulosa cell tumorDormant
CCC
Indicative ·
50 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →